A Phase 1 interventional study of MK-8527 in Human Immunodeficiency Virus and AIDS Virus, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in Romania. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-09-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Acquired Immunodeficiency Syndrome by Merck & Co., Inc — 4 open to participants now, 6 under way, 3 of them phase 3. Acquired Immunodeficiency Syndrome · Merck & Co., Inc.
Among the 37 studies in Acquired Immunodeficiency Syndrome by Merck & Co., Inc, this one is the 22nd largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2019, is one of 11 in phase 1, and was the 22nd registered.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →4 of the 37 studies in Acquired Immunodeficiency Syndrome by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Canada and 6 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Kenya, South Africa, Uganda
Ages 16–30 · Women only · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States, Colombia, Dominican Republic and 5 more countries
Ages 4 wk–11 yrs
Merck Sharp & Dohme LLC
Ages 18–60
By country, each count listing its studies:
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 11 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 82 across the 34 interventional studies, 257 across the 2 observational. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
4 of the studies in Acquired Immunodeficiency Syndrome by Merck & Co., Inc that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07044297Phase 3Merck Sharp & Dohme LLCA Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | 2027-07-22 |
| NCT07071623Phase 3Merck Sharp & Dohme LLCA Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) | 2027-10-18 |
| NCT07600775Merck Sharp & Dohme LLCA Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019) | 2027-01-19 |
| NCT06891066Merck Sharp & Dohme LLCA Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060) | 2027-08-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 37 studies in Acquired Immunodeficiency Syndrome by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the anti-retroviral activity of MK-8527 in HIV-1 infected, ART-naïve participants. The primary hypothesis is that MK-8527 has superior anti-retroviral activity compared to placebo, as measured by change from baseline in plasma HIV-1 ribonucleic acid (RNA) at 168 hours postdose.
Up to five panels (Panels A-E) of 6 participants each will be enrolled in a sequential manner. In each panel, participants will receive a single dose of MK-8527 up to 50 mg. Historical data from previous single does studies will be used for placebo (control) comparisons.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of 10 mg MK-8527 capsule after an 8-hour fast
Drug: MK-8527
Single oral dose of 3 mg MK-8527 capsule after an 8-hour fast
Drug: MK-8527
Single oral dose of 1 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
Drug: MK-8527
Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
Drug: MK-8527
Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
Drug: MK-8527
Single oral capsule
Change From Baseline in Plasma HIV-1 RNA
Blood samples were taken to determine HIV-1 RNA levels at Predose (baseline) and 168 hours postdose. Data were fitted with a longitudinal data analysis (LDA) model containing fixed effects for treatment, time and treatment by time interaction, and a random effect for participant.The change from baseline in plasma HIV-1 RNA in participants administered MK-8527 was calculated and results were compared with historical placebo data.
Time frame: Baseline and 168 hours postdose
Percentage of Participants Who Report 1 or More Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it is considered related to the medicinal product. The percentage of participants that reported at least 1 AE will be summarized.
Time frame: Up to 28 days
Percentage of Participants Who Were Discontinued From the Study Due to an AE
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it is considered related to the medicinal product. The percentage of participants that were discontinued from the study due to an AE will be summarized.
Time frame: Up to 28 days
Area Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527-TP in Peripheral Blood Mononuclear Cells (PBMC)
Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-168 of MK-8527-triphosphate (MK-8527-TP) in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% confidence intervals (CI) for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 4, 12, 24, 96, 120, 144, and 168 hours postdose
Area Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527-TP in PBMC
Blood samples were taken at Predose, up to approximately 28 days postdose to determine the AUC0-last of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose
Area Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527-TP in PBMC
Blood samples were taken at Predose, up to approximately 28 days postdose to determine the AUC0-Inf of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose
Maximum Concentration (Cmax) of MK-8527-TP in PBMC
Blood samples were taken at Predose, up to approximately 28 days postdose to determine the Cmax of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose
Time to Cmax (Tmax) of MK-8527-TP in PBMC
Blood samples were taken at Predose, up to approximately 28 days postdose to determine the Tmax of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose
Concentration at 168 Hours (C168) of MK-8527-TP in PBMC
Blood samples were taken at 168 hours postdose to determine the C168 of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: 168 hours postdose for each panel
Apparent Terminal Half Life (t1/2) of MK-8527-TP in PBMC
Blood samples were taken at Predose, up to approximately 28 days postdose to determine the t1/2 of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 240, 336, 504, 672 hours or 28 days postdose
Area Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527 in Plasma
Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-168 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Area Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527 in Plasma
Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-last of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Area Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527 in Plasma
Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-inf of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Maximum Concentration (Cmax) of MK-8527 in Plasma
Blood samples were taken at Predose, up to 168 hours postdose to determine the Cmax of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Time to Cmax (Tmax) of MK-8527 in Plasma
Blood samples were taken at Predose, up to 168 hours postdose to determine the Tmax of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Concentration at 168 Hours (C168) of MK-8527 in Plasma
Blood samples were taken at 168 hours postdose to determine the C168 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: 168 hours postdose
Apparent Terminal Half Life (t1/2) of MK-8527 in Plasma
Blood samples were taken at Predose, up to 168 hours postdose to determine the t1/2 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 168 hours postdose
Anti-retroviral therapy (ART)-naïve, participants with human immunodeficiency type 1 virus (HIV-1) infection were enrolled in this study.
| Milestone | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg | Panel D: ≤50 mg MK-8527 | Panel E: ≤50 mg MK-8527 |
|---|---|---|---|---|---|
| Started | 6 | 6 | 5 | 0 | 0 |
| Completed | 6 | 6 | 5 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Blood samples were taken to determine HIV-1 RNA levels at Predose (baseline) and 168 hours postdose. Data were fitted with a longitudinal data analysis (LDA) model containing fixed effects for treatment, time and treatment by time interaction, and a random effect for participant.The change from baseline in plasma HIV-1 RNA in participants administered MK-8527 was calculated and results were compared with historical placebo data.
| log10 copies/mL | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Change From Baseline in Plasma HIV-1 RNA | -1.39 (-1.78 to -0.99) | -1.66 (-2.06 to -1.27) | -0.95 (-1.38 to -0.52) |
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it is considered related to the medicinal product. The percentage of participants that reported at least 1 AE will be summarized.
| Percentage of participants | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Percentage of Participants Who Report 1 or More Adverse Events (AEs) | 0 | 33.3 | 0 |
An AE is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it is considered related to the medicinal product. The percentage of participants that were discontinued from the study due to an AE will be summarized.
| Percentage of participants | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Percentage of Participants Who Were Discontinued From the Study Due to an AE | 0 | 0 | 0 |
Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-168 of MK-8527-triphosphate (MK-8527-TP) in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% confidence intervals (CI) for the means were constructed on the natural log scale and referenced the t-distribution.
| hr*pmol/10^6 cells | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Area Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527-TP in Peripheral Blood Mononuclear Cells (PBMC) | 178 (140 to 226) | 64.1 (50.5 to 81.3) | 29.1 (22.4 to 37.7) |
Blood samples were taken at Predose, up to approximately 28 days postdose to determine the AUC0-last of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| hr*pmol/10^6 cells | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Area Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527-TP in PBMC | 235 (182 to 302) | 108 (84 to 139) | 49.5 (37.5 to 65.3) |
Blood samples were taken at Predose, up to approximately 28 days postdose to determine the AUC0-Inf of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| hr*pmol/10^6 cells | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Area Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527-TP in PBMC | 265 (206 to 342) | 146 (113 to 188) | 55.0 (41.6 to 72.8) |
Blood samples were taken at Predose, up to approximately 28 days postdose to determine the Cmax of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| pmol/10^6 cells | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Maximum Concentration (Cmax) of MK-8527-TP in PBMC | 1.81 (1.40 to 2.35) | 0.644 (0.497 to 0.834) | 0.265 (0.200 to 0.352) |
Blood samples were taken at Predose, up to approximately 28 days postdose to determine the Tmax of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| Hours | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Time to Cmax (Tmax) of MK-8527-TP in PBMC | 18.00 (12.00 to 24.00) | 24.00 (12.00 to 24.00) | 24.00 (12.00 to 96.63) |
Blood samples were taken at 168 hours postdose to determine the C168 of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| pmol/10^6 cells | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Concentration at 168 Hours (C168) of MK-8527-TP in PBMC | 0.509 (0.371 to 0.698) | 0.334 (0.244 to 0.458) | 0.0978 (0.0692 to 0.138) |
Blood samples were taken at Predose, up to approximately 28 days postdose to determine the t1/2 of MK-8527-TP in PBMCs. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| Hours | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Apparent Terminal Half Life (t1/2) of MK-8527-TP in PBMC | 117.84 ± 35.00 | 188.66 ± 122.5 | 210.93 ± 14.62 |
Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-168 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| hr*μmol/L | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Area Under the Concentration Time Curve From Hour 0 to 168 Hours (AUC0-168) of MK-8527 in Plasma | 0.926 (0.719 to 1.19) | 0.152 (0.118 to 0.196) | 0.0189 (0.0138 to 0.0258) |
Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-last of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| hr*μmol/L | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Area Under the Concentration Time Curve From Hour 0 to Last (AUC0-last) of MK-8527 in Plasma | 0.880 (0.669 to 1.16) | 0.121 (0.0919 to 0.159) | 0.0151 (0.0112 to 0.0204) |
Blood samples were taken at Predose, up to 168 hours postdose to determine the AUC0-inf of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| hr*μmol/L | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Area Under the Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-8527 in Plasma | 1.10 (0.794 to 1.53) | 0.196 (0.141 to 0.272) | NA (NA to NA) |
Blood samples were taken at Predose, up to 168 hours postdose to determine the Cmax of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| μmol/L | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Maximum Concentration (Cmax) of MK-8527 in Plasma | 0.177 (0.114 to 0.276) | 0.0371 (0.0238 to 0.0577) | 0.0162 (0.00998 to 0.0264) |
Blood samples were taken at Predose, up to 168 hours postdose to determine the Tmax of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| Hours | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Time to Cmax (Tmax) of MK-8527 in Plasma | 0.50 (0.50 to 1.00) | 0.50 (0.50 to 1.00) | 0.50 (0.50 to 0.50) |
Blood samples were taken at 168 hours postdose to determine the C168 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| μmol/L | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Concentration at 168 Hours (C168) of MK-8527 in Plasma | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Blood samples were taken at Predose, up to 168 hours postdose to determine the t1/2 of MK-8527 in plasma. Values were natural log transformed and analyzed based on a linear model containing a fixed effect for dose level. The 95% CI for the means were constructed on the natural log scale and referenced the t-distribution.
| Hours | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| Apparent Terminal Half Life (t1/2) of MK-8527 in Plasma | 40.31 ± 60.27 | 12.36 ± 78.23 | NA ± NA |
Collected over Up to 28 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panel A: MK-8527 10 mg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Panel B: MK-8527 3 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Panel C: MK-8527 1 mg | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Event | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg |
|---|---|---|---|
| PharyngitisInfections and infestations | 0/6 | 1/6 | 0/5 |
| DizzinessNervous system disorders | 0/6 | 1/6 | 0/5 |
| InsomniaPsychiatric disorders | 0/6 | 1/6 | 0/5 |
Panels D and E were not conducted as the scientific study objectives were met in the conducted panels.
| Age, Continuous(Years) | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg | Panel D: ≤50 mg MK-8527 | Panel E: ≤50 mg MK-8527 | Total |
|---|---|---|---|---|---|---|
| Mean | 28.8 ± 2.3 | 33.3 ± 9.0 | 31.2 ± 5.6 | — | — | 31.1 ± 6.2 |
| Sex: Female, Male(Participants) | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg | Panel D: ≤50 mg MK-8527 | Panel E: ≤50 mg MK-8527 | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 1 | 0 | — | — | 3 |
| Male | 4 | 5 | 5 | — | — | 14 |
| Ethnicity (NIH/OMB)(Participants) | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg | Panel D: ≤50 mg MK-8527 | Panel E: ≤50 mg MK-8527 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | — | — | 0 |
| Not Hispanic or Latino | 6 | 6 | 5 | — | — | 17 |
| Unknown or Not Reported | 0 | 0 | 0 | — | — | 0 |
| Race (NIH/OMB)(Participants) | Panel A: MK-8527 10 mg | Panel B: MK-8527 3 mg | Panel C: MK-8527 1 mg | Panel D: ≤50 mg MK-8527 | Panel E: ≤50 mg MK-8527 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | — | — | 0 |
| Asian | 0 | 0 | 0 | — | — | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | — | — | 0 |
| Black or African American | 0 | 0 | 0 | — | — | 0 |
| White | 6 | 6 | 5 | — | — | 17 |
| More than one race | 0 | 0 | 0 | — | — | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2019 to primary completion in Sep 2019, 7 months.
Results were first posted in Sep 2020, 1 year after primary completion.
Of 76 industry-sponsored phase 1 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 7 months is above that.
Counting every sponsor, half of 139 studies reached it within 14 months; a quarter within 4 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alimatravir
Acquired Immunodeficiency Syndrome →